Effects of Testosterone in Women With Depression

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

The purpose of the study is to determine whether adding a low dose of testosterone to current antidepressant therapy improves depression and fatigue in women who remain depressed despite necessary adequate doses of anti-depressants. Testosterone will be given over an 8-week period.

Testosterone is a hormone that occurs naturally in the body. In women it comes from the ovaries and adrenal glands and is found in amounts that are ten to twenty times lower than in men.

In early research studies, testosterone has been shown to have some antidepressant effects in the following groups of subjects:

• Women with anorexia nervosa
• Women who have low testosterone levels because their pituitary glands do not work
• Men with Selective Serotonin Reuptake Inhibitor (SSRI)-resistant depression.

However, testosterone administration in women with SSRI or Serotonin-norepinephrine reuptake inhibitor (SNRI) -resistant depression has not been studied.

Condition or disease	Intervention/treatment	Phase
Depression	Drug: Testosterone	Not Applicable

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	9 participants
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Effects of Testosterone in Women With Depression: A Pilot Study
Study Start Date :	March 2007
Actual Primary Completion Date :	October 2008
Actual Study Completion Date :	October 2008

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Active Comparator: Testosterone; Testosterone patch delivering 300mcg daily for 8-weeks.	Drug: Testosterone; Testosterone atch delivering 300mcg daily for 8-weeks

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Montgomery-Asberg Depression Rating Scale (MADRS) Scale [ Time Frame: Baseline, 2-week, 8-week ]
   the MADRS is a diagnostic questionnaire that is used to measure the severity of depressive episodes in patients with mood disorders. The minimum and maximum values are 0 and 60 respectively (higher scores are more severe).

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years to 75 Years (Adult, Senior)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• Female, age 18-75
• Written informed consent
• Meet Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria (by Structured Clinical Interview for DSM-IV (SCID)) for Major Depressive Disorder
• Meet DSM-IV criteria for a current major depressive episode, as assessed by SCID
• Montgomery-Asberg Depression Rating Scale (MADRS) greater than or equal to 16 at baseline visit
• Currently treated with SSRI or SNRI, with or without adjunctive therapy, at an adequate dose (see adequate dose table below) for at least six weeks

Exclusion Criteria:

• Pregnant women or women of child bearing potential who are not using a medically accepted means of contraception (to include oral contraceptive or implant, condom, diaphragm, spermicide, intrauterine device, tubal ligation, or partner with vasectomy)
• Serious suicide or homicide risk, as assessed by evaluating clinician
• Unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic (including uncontrolled seizure disorder)
• Substance use disorder active within last six months
• Psychotic features (current episode or lifetime), as assessed by SCID
• Laboratory evidence of untreated hypothyroidism
• If treated hypothyroidism, significant change in levo-thyroxine dose within the prior three months
• If receiving oral estrogen therapy, including oral contraceptives or transdermal estrogen therapy, significant change in dose in the prior three months
• Use of androgens or androgen precursors, including testosterone, Dehydroepiandrosterone (DHEA) and methyltestosterone, within the prior three months
• Any investigational psychotropic drug within the last two weeks
• In the judgment of the study clinician, unlikely to be able to participate safely throughout the study period (three or more episodes of self-harm in the past year, documented history of poor treatment adherence, or frequent missed appointments (greater than 50%) in the past year)
• Alanine aminotransferase (ALT) greater than 1.5 times the upper limit of normal.
• Creatinine greater than 1.5 times upper limit of normal
• History of a hormone-responsive cancer
• History of congestive heart failure
• MADRS greater than 31

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Sponsors and Collaborators

Massachusetts General Hospital

National Institutes of Health (NIH)

Investigators

Principal Investigator:	Karen K Miller, MD	Massachsuetts General Hospital

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Karen Klahr Miller, MD, Principal Investigator, Massachusetts General Hospital
ClinicalTrials.gov Identifier:	NCT00676676 History of Changes
Other Study ID Numbers:	2007p000348
First Posted:	May 13, 2008
Results First Posted:	November 30, 2012
Last Update Posted:	November 30, 2012
Last Verified:	November 2012

Keywords provided by Karen Klahr Miller, MD, Massachusetts General Hospital:

Depression; Major Depressive Disorder

Additional relevant MeSH terms:

Depression; Depressive Disorder; Behavioral Symptoms; Mood Disorders; Mental Disorders; Testosterone; Testosterone enanthate; Testosterone undecanoate; Testosterone 17 beta-cypionate	Methyltestosterone; Androgens; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Physiological Effects of Drugs; Antineoplastic Agents, Hormonal; Antineoplastic Agents; Anabolic Agents